StockWatch
·

Fortress Biotech, Inc. Q3 FY26 Results

FBIOQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue19.162.4%8.7%
Total Income19.162.4%8.7%
Expenditure26.358.3%7.8%
PBT-8.311003.3%193.9%
Net Profit-5.851144.7%200.0%
OPM-37.54%15.91pp1.09pp
NPM-30.51%28.01pp63.69pp
EPS-0.23187.5%276.9%
View full financials

Fortress Biotech Reports Q3 2026 Financial Results and Corporate Highlights

13 Nov 2026 · 13 Nov, 6:36 pm

Summary

Fortress Biotech announced its financial results for the third quarter ended September 30, 2026, reporting total net revenue of $19.2 million, a 9% increase year-over-year. The company highlighted significant corporate updates, including the full repayment of its credit facility and the in-licensing of FB-607 for IBS-D. Management expressed confidence in the company's diversified portfolio and its position to drive long-term shareholder value.

Key Highlights

  1. 1

    Fortress Biotech reported total net revenue of $19.2 million for the third quarter of 2026, an increase of approximately 9% compared to the third quarter of 2025.

  2. 2

    Journey Medical reported net product revenues of $18.9 million for the third quarter of 2026, up from $17.0 million in the prior year's third quarter.

  3. 3

    Fortress repaid its credit facility in full in September 2026, settling the remaining $15.0 million in outstanding principal.

  4. 4

    A subsidiary of Fortress entered into a license agreement for FB-607, a novel drug for IBS-D, in the third quarter of 2026.

  5. 5

    In September 2026, anselamimab (formerly CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis.

  6. 6

    Consolidated net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share basic and diluted, for the third quarter ended September 30, 2026.

Management Comments

L

Lindsay A. Rosenwald

The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”). FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027. Journey Medical continues to build momentum with Emrosi®, with approximately 40,000 in total prescriptions for the third quarter of 2026, supported by continued improvement in the mix of prescriptions reimbursed by health plans. Additionally, in September, anselamimab (formerly CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis. With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.

Informational and educational content only. Not investment advice.